TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

250 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

144 studies on the map

Molecular Signatures of Cutaneous Dupilumab Response — University of California, San Francisco, San FranciscoEvaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity — University of Connecticut, StorrsA Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring — Pfizer, New YorkThis Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis. — Washington University in St. Louis, St LouisTargeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial — Sidney & Lois Eskenazi Hospital, IndianapolisEvaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain — Shirley Ryan AbilityLab, ChicagoTreatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation — The University of Texas at Dallas, RichardsonEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. — Perseverance Research Center, ScottsdaleA Study to Learn About Study Medicine Called PF-08049820 in People With Eczema — Northridge Clinical Trials, NorthridgeNARCOMS Registry: A Multiple Sclerosis Registry — UT Southwestern Medical Center, DallasA Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome — Clinical Research Institute of Arizona, Sun City WestPrescription of Step Counts for Targeted Changes in Body Composition and Cardiometabolic Risk in Overweight/Obese Adults — Kennesaw State Universityh, Kennesaw"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS — University of California, San Francisco, San FranciscoStudy to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab — TG Therapeutics Investigational Trial Site, BirminghamA Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS) — Neurology Center of New England P.C., FoxboroughAn Open-label Study of AZD0120 in Adults With Multiple Sclerosis — Research Site, TucsonUblituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis — Northwestern Memorial Hospital, ChicagoA Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors — UConn Health, FarmingtonEffect of Cooling on Balance Performance in Multiple Sclerosis — Hunter College, Physical Therapy Department, City University of New York, New YorkEvaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaMetabolic Profiling of Immune Responses in Immune-mediated Diseases — National Institutes of Health Clinical Center, BethesdaCardamom and Topical Roseomonas in Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaA Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases — Stanford Neuroscience Health Center, Palo AltoDalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis — MGH Institute of Health Professions, BostonRegistry for Systemic Eczema Treatments — Johns Hopkins University, BaltimoreA Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis — Stanford Multiple Sclerosis Center, Palo AltoA Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up — National Institutes of Health Clinical Center, BethesdaHome Based Functional Balance Intervention for Multiple Sclerosis — University of Illinois at Chicago, ChicagoNeuromodulating Cortical Regions Involved in Neurogenic Bladder in MS — Houston Methodist Hospital, HoustonA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity — Alabama Neurology Associates, BirminghamBringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients — University of Michigan, Ann ArborReal-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults — Galderma Investigational Site - 8893, BirminghamBreathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases — Mayo Clinic in Rochester, RochesterA Long-Term Follow-Up Study for Participants Previously Treated With KYV-101 — University of Colorado, Denver, DenverA Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis — Investigational Site, Fountain ValleyA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema — Cahaba Dermatology & Skin Health Center, LLC, BirminghamA Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) — First OC Dermatology, IrvineA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis — Arizona Neuroscience Research, LLC, PheonixDupilumab De-escalation in Pediatric Atopic Dermatitis — Johns Hopkins Univerisity, BaltimoreA Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Profound Research, LLC, CarlsbadA Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk — PROVIDE Virtual Research Coordination Center, San FranciscoDeciphering Preserved Autonomic Function After Multiple Sclerosis — Mayo Clinic, RochesterNatural History and Genetics of Food Allergy and Related Conditions — National Institutes of Health Clinical Center, BethesdaA Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis — Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute, PhoenixIConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis — Accelerated Cure Project, WalthamPathological Basis of MRI Signal Changes in Multiple Sclerosis — National Institutes of Health Clinical Center, BethesdaEffect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques — National Institutes of Health Clinical Center, BethesdaFall Prevention Among People With Spinal Cord Injury and Multiple Sclerosis Who Use Wheelchairs and Scooters — Disability Participation and Quality of Life (DPQOL) Laboratory, UrbanaBest Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) — Stanford Multiple Sclerosis Center, Palo AltoStudy to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population — Syneos Health (remote site), MorrisvilleThe SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study — Shepherd Center, AtlantaWearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study — Norman Fixel Institute for Neurological Diseases, GainesvilleSolriamfetol for the Treatment of Multiple Sclerosis Fatigue — Johns Hopkins University, BaltimoreA Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis — Inmagene Site 1, LancasterStudy to Evaluate Soquelitinib in Participants With Moderate to Severe AD — Corvus Clinical Trials, South San FranciscoEntire-body PET Scans for Multiple Sclerosis — Brain Health Alliance, Ladera RanchFlourish: Exploring the Early Infant Gut Microbiome — Seeding Labs INC, AustinPh 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 — Clinical Site 101, Fair LawnA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis — Arizona Neuroscience Research, LLC, PhoenixInvestigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis — Wayne State University, DetroitA Palliative Care Model Impact on Knowledge and Attitudes — Judith Jaffe Multiple Sclerosis Center, New YorkCottonseed Oil Versus Matched PUFA Effects — University of Georgia, AthensEffects of Acute Intermittent Hypoxia on Neuroplasticity in MS — Shirley Ryan AbilityLab, ChicagoCare in Multiple Sclerosis (MS) — University of Alabama at Birmingham, BirminghamA Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis — Stanford University Medical Center, StanfordHome Based Infusions for Ocrelizumab — Amerita, CentennialA Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis — Kessler Foundation, East HanoverStudy to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis — Local Institution - 0114, Loma LindaExercise Rehabilitation Program in MS Who Use Wheelchairs as a Primary Mobility Device — University of Illinois at Chicago, ChicagoTreatment of Participants With Primary or Secondary Progressive Multiple Sclerosis — University of Kansas Medical Center, Kansas CityAIM's Writing for Healing: A Workshop for Individuals Living With Paralysis — 354 School of Health Professions Building, BirminghamTreatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome — Icahn School of Medicine at Mount Sinai, New YorkA Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis — Hamilton Research, LLC, AlpharettaNYSCF Scientific Discovery Biobank — New York Stem Cell Foundation Research Institute, New YorkCentral Vein Sign in Multiple Sclerosis Extension Study — Cedars-Sinai Medical Center, Los AngelesA Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) — TG Therapeutics Investigational Trial Site, BirminghamA Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS) — BRIUMVI® Pregnancy Registry Virtual Research Coordination Center, WilmingtonSodium in the Skin and Atopic Dermatitis — San Francisco VA Medical Center, San FranciscoInvestigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS — Kessler Foundation, West OrangeA Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) — Local Institution - 0011, BirminghamTargeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis — Johns Hopkins University, BaltimoreLebrikizumab in Moderate-to-severe Atopic Dermatitis — Physioseq USA - CA, FolsomSkeletal Muscle Aging and Responsiveness in Aged People With MS — Oklahoma Medical Research Foundation, Oklahoma CityExploring the Utility of [18F]3F4AP for Demyelination Imaging — Yale University PET Center, New HavenMotor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis — Georgia State University Biomechanics Lab, AtlantaCorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry — CorEvitas, LLC, WalthamA Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis — Applied Research Center Of Arkansas /ID# 268547, Little RockExercise Training for Managing Major Depressive Disorder in Multiple Sclerosis — University of Illinois at Chicago, ChicagoPrepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS? — Jacobs School of Medicine and Biomedical Sciences, Neurology, University at Buffalo, BuffaloHyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis — Byers Hall, San FranciscoTopical Treatment for Atopic Dermatitis — Wake Forest University Health Sciences, Winston-SalemPharmacy-led Transitions of Care Intervention to Improve Medication Adherence — University of Tennessee Medical Center, KnoxvilleHOBSCOTCH-MS-Efficacy Trial — Dartmouth-Health Lebanon, LebanonNon-invasive BCI-controlled Assistive Devices — The University of Texas at Austin, AustinMS-ResearchBiomarkerS — Cedars-Sinai Medical Center, Los AngelesA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis — Alabama Neurology Associates PC, BirminghamThe Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis — University of Pittsburgh Medical Center, PittsburghEthnic Differences in Mechanisms of Action of Dupilumab — University of Michigan, Ann ArborInspire HER: Inspiring the Heart and Emotions for Radical Health — University of Alabama at Birmingham, BirminghamIntermittent Cottonseed Oil Consumption — University of Georgia, AthensDevelopment of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis — Shirley Ryan AbilityLab, ChicagoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis — AllerVie Clinical Research, BirminghamIncreasing Physical Activity for Adults With Multiple Sclerosis (MS) — UW Medicine, SeattleSafety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis — Red River Research Partners, FargoProspective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod — University of Colorado Anschutz Medical Campus, AuroraIntermittent Hypoxia in Persons With Multiple Sclerosis — Shirley Ryan AbilityLab, ChicagoFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients — Anaheim Clinical Trials, LLC, AnaheimA Study of the MIND Diet for Persons With Multiple Sclerosis — Mount Sinai Hospital, New YorkA 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis — Sitryx Clinical Site, Arkansas CityStudy of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis — Johns Hopkins University, BaltimoreConfirmatory Trial for Alleviating Fatigue in Multiple Sclerosis — Washington VA Medical Center, Washington D.C.Interprofessional Pharmacogenomics (IPGx) Registry and Repository — Texas A&M Family Care, BryanSmoldering Inflammation in MS — Barnes Jewish Center for Clinical Imaging Research, St LouisMetformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS) — UBMD Neurolgy, BuffaloPregnancy Exposure Registry for Vumerity (Diroximel Fumarate) — University of Colorado Anschutz Medical Campus, AuroraMichigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project — University of Michigan, Ann ArborA Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis — Leo Pharma Investigational site, BirminghamGlucose Consumption in MS Using [F-18]FDG-PET — Brigham & Women's Hospital, BostonTargeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) — University of California, San Diego: Dermatology Clinical Trials Unit, San DiegoIntestinal Immunity in Neurologic Disease — Yale MS Clinic, North HavenA Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis — AllerVie Clinical Research, BirminghamImaging the Pathogenesis of Cerebral Small Vessel Disease — Kennedy Krieger Institute, BaltimoreA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab — Physioseq, LLC /ID# 267266, SacramentoMilitary Health and Nutrition Examination Study — Fort Campbell, Fort CampbellA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab — Cahaba Dermatology & Skin Health Center /ID# 263855, BirminghamSilodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis — Atlantic Health, MorristownHealthy Living Anson Study — University of North Carolina at Chapel Hill, Chapel HillEvaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis — First OC Dermatology, Fountain ValleyObe-cel in Refractory Progressive Forms of Multiple Sclerosis — Stanford University, Redwood CityTesting the Feasibility of Computer-based Cognitive Training in Individuals with Multiple Sclerosis Living in the Community — Kessler Foundation, East HanoverPregnancy Registry, Infants, Serum/Milk Analysis (PRISMA) — University of California-San Francisco, San FranciscoEffects of Torso Weighting on Muscle Activation During Balance Tests in Individuals With and Without Multiple Sclerosis — University of St. Augustine for Health Sciences, Saint AugustineFunctional Balance Intervention in Multiple Sclerosis — University of Illinois at Chicago, ChicagoAssessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy — Sandler Neurosciences Building, Neurological Clinical Research Unit, San FranciscoDry Needling in Multiple Sclerosis — Mobility and Falls Lab, Kansas CityNasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis — Brigham and Women's Hospital, BostonExploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis — University of Maryland, Baltimore, BaltimoreNon-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis — University of Washington, SeattleVascular Mechanisms, Functional Outcomes, & Exercise Among Persons With Multiple Sclerosis With Hypertension — UMass Boston, BostonA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) — ALS Global, IrvingReal World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies. — Pfizer, New YorkA Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis — Nektar Investigative Site, St. PetersburgEfficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis — University of Kansas Medical Center, Kansas CityComparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection — University of Kansas Medical Center- Sleep, Health and Wellness Laboratory, Kansas City

Showing the 150 nearest — narrow your filters for fewer, closer studies.